Tag Archives: anti-arrhythmia agents

Introduction Atrial fibrillation is the most common arrhythmia, affecting 1–2% of the population.1 It is associated with an increased risk of stroke and death, heart failure, reduction in quality of life, mental health problems and cognitive impairment.2 Hospitalisation is common and costly.3 Dronedarone was first approved by the National Institute for Health and Care Excellence (NICE) in April 20104 for atrial fibrillation rhythm control, but following two fatal cases of liver toxicity it is contraindicated in patients with liver dysfunction, a creatinine clearance (CrCl) ≤30 ml/min, in permanent atrial fibrillation or congestive heart f